A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01838317|
Recruitment Status : Completed
First Posted : April 24, 2013
Last Update Posted : May 15, 2018
|Condition or disease||Intervention/treatment||Phase|
|Cancer of the Pancreas||Drug: Pioglitazone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||14 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||September 20, 2017|
|Actual Study Completion Date :||September 20, 2017|
- Improvement in insulin resistance markers [ Time Frame: Baseline 4 weeks and 8 weeks of treatment ]
- Change in serum adiponectin level. We will obtain serum levels of adiponectin at baseline and after 8 weeks of treatment with pioglitazone.
- Changes in standard glucose tolerance test. We will perform the area under the oral glucose tolerance test at baseline and after 8 weeks of treatment with pioglitazone.
- Fasting levels of serum glucose and insulin. We will obtain serum levels of fasting glucose and insulin every four weeks in all patients receiving pioglitazone
- Change in weight [ Time Frame: Every 2 weeks for 10 weeks ]To describe changes in weight in patients with pancreas cancer receiving pioglitazone.
- ECOG Performance Status [ Time Frame: Every 2 weeks for 10 weeks ]Changes in ECOG performance status in patients with pancreas cancer receiving pioglitazone.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01838317
|United States, Texas|
|UT Southwestern Medical Center|
|Dallas, Texas, United States, 75390|
|Principal Investigator:||Muhammad Beg, MD||UT Southwestern Medical Center|